Which drugs go off patent in 2030?
One blockbuster drug with $3.6B in 2025 worldwide sales loses US exclusivity in 2030: Taltz (Eli Lilly).
| Drug | Company | Area | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Taltz | Eli Lilly | Immunology | $3.6B | Company guidance | In clinical trials | – |
Every date here is fixed by a launch, settlement, court ruling or company guidance. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Eli Lilly | Taltz | $3.6B | 5.5% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Biosimilars usually erode a biologic's sales more gradually, because they are harder to make and switching takes longer.
US exclusivity can end earlier or later than these dates if a court ruling, settlement or new patent changes the picture. See what happened to sales after past patent cliffs →